Showing posts with label myeloproliferative neoplasms. Show all posts
Showing posts with label myeloproliferative neoplasms. Show all posts

Wednesday, June 26, 2013

Jakafi to the Rescue


Myelofibrosis Treatment Banishes Behcet's... Coincidence? I think Not

About one month after my Autumn 2009 PV (polycythemia vera) diagnosis, I started getting unexplainable lesions in most inconvenient locations (I've shared this over a year ago). After several months of excluding many possibilities, it was diagnosed as "Behcet's Disease/Syndrome" or "Probably Behcet's" in March, 2010.  

I found it odd that I would acquire an MPN (myeloproliferative neoplasm) and an auto-immune disease around the same time (mid-40's). My internist said anything is possible; my hem/onc and rheumatologist said there was no connection. 

While the medical literature didn't show any links with Myeloproliferative Neoplasms (MPNs) and auto-immune diseases, the question persisted in my mind.

Chemical Reactions or Physiological Changes?

I took Hydroxyurea (HU) to manage the polycythemia vera, along with occasional phlebotomies. When the Behcet's became unbearable, I was treated with prednisone for over a year to manage the flares. I then switched to Remicade infusions when I couldn't stand all the side effects of prednisone. The Remicade worked like a dream for six months. The last six months of using it, however, I endured debilitating inflammation and joint pain. My rheumatologist pointed to the PV and my hem/onc pointed to the Behcet's. Even getting second opinions in both fields kept me in a painful mobius loop.   

Last November, a gastroenterologist friend said that the inflammation symptoms were consistent with what some of his Crohn's patients experience after a time on Remicade.  I was in a conundrum: which pain do I prefer -- the hands, feet, and joint pain or the lesions pain in other equally important body parts. It was a false choice. 

At the same time, all my blood counts were on a slow but stead descent and we knew something new was happening. I quit taking the Remicade and decided to use prednisone when a flare was just beginning. It took about eight weeks for the Remicade to fully leave my body.

Enter Jakafi... After being diagnosed with post-PV Myelofibrosis in February 2013, I began a low-dose regimen of Jakafi to shrink my spleen, ease bone pain and night sweats.

My last Behcet's encounter was the first week I started Jakafi. I hit it with prednisone to keep it from going full flare. It subsided within 4 days. I haven't had another flare since.

Apparently, there has been research on the JAK pathways and their relationship to auto-immune diseases. Pfizer now has TV ads for Xeljanz (tofacitinib), a "JAK inhibitor for Rheumatoid Arthritis."  RA is another auto-immune disease.

I realize that I am but a sample of one, but this experience gives me solace that my hunch that these two rare/oddball diseases share something in common. The JAK pathway!

When Focus Needs Perspective  

We are living in a most remarkable time of scientific discovery. 
Researchers are able to focus on changes at the molecular level and tie to proteins, genes, kinases and other terms I can barely pronounce.  

Many times I've been frustrated by the very narrow scope of this research because it doesn't help me NOW when I'm hurting. 

I must remember the adage: Follow the money. 
Research funding is tied to very specific research questions and tight timeframes, influenced by the funder(s). Funding is extremely competitive. And those research dollars rarely fully-fund a project, much less encourage researchers to follow new paths that emerge as they do their work. 

So blood cancer researchers continue their diligent work and auto-immune disease researchers continue their work. All the work is vital to understanding the disease processes which will ultimately inform us on effective prevention strategies. 

At the same time, a funding mechanism that supports tying all this knowledge together must occur to make the whole larger than the sum of its parts.
Stand Up to Cancer is a funder of innovative and collaborative research and information sharing among experts of different types of cancers.  

Perhaps it's up to patients/trial subjects (whole beings) to share our experiences, observations and questions. We can help the subject matter experts "connect the dots" in ways that may be outside a study protocol, but useful nonetheless.

After all, we are not only the patients, we are the consumers of the eventual treatment or cure.

Monday, February 18, 2013

These Tired Bones Need a Makeover

After several days of tests and consultations with experts at Mayo Clinic Scottsdale, I returned home with a worse-than-expected diagnosis. Here's the quickie Bad News/Good News version:

My bone marrow has gone from over-achievement to under-achievement. Instead of producing too many red blood cells, it is now in the "spent phase" and is not producing enough blood. This transition called my spleen and liver into action to produce blood. They are working hard, but will not be able to sustain their efforts forever. I'll soon need blood transfusions to keep my hemoglobin at a livable level. What irony! From phlebotomy to transfusion in less than one year.

A blood stem cell transplant is in my near future;  a successful transplant will cure me of the myelofibrosis AND the auto-immune conditions that rage inside.
Without a transplant, I'm at great risk for acute leukemia (no cures) and could expect less than three years on the sunny side of the ground.

Now that the test results and reports from Mayo are in my local doctors' hands, I'm preparing for the insurance approval / denial / appeal process. Quite frankly, I'm more anxious about getting the transplant approved (with the best transplant center for my particular leukemia) than the transplant process itself.

The kids and Robert are taking the news like champs. So are my mom, dad, and siblings. We're going to get through this together as we do all challenges ~ with love, laughter, the occasional cuss word, and toasts to the present and a bright future. 

Some have asked what they can do to help.  If you are so inclined, please consider:

  1. Become a blood donor. You can be sure that me, or someone like me, is grateful for your gift of life.
  2. Join the National Bone Marrow Donor Program. With a simple swab of your cheek, you will be "typed" (not blood type, by the way) and entered into the database. When a patient needs a donor, our info is compared. Donors are contacted and must agree to be considered for donation before the patient is contacted. Donors can say no at any time. Also, I won't need your bone marrow ~ just your blood stem cells (it's like donating platelets).
  3. Keep us in your happy thoughts, prayers, meditations. My mom alerted her international, multi-faith 'God Squad' and I am here to tell you that I do feel the love. It manifests in hope, energy, and strength.  


NOTE:  I especially encourage my friends of Asian, African, Jewish, and Native American descent to sign up. Matches for are very limited for children and adults of color compared to white European descendants. 

Here are some specialty donor programs (they tie into the large database):  




#  #  #

If you like more technical terms, read on:


I. My Polycythemia Vera (PV) has transformed to post-polycythemic Myelofibrosis (MF) in recent months.

  • I have completed the “spent phase” of Polycythemia Vera and my bone marrow now has lots of reticulin, which crowds out the blood-making stem cells. 
  • Extra-medullary hematopoiesis is now at work – the spleen and liver are beginning to produce blood due to the bone marrow fibrosis.  Over time, this puts extreme stress on both organs.
  • The overall goal is to prevent the MF from progressing to an acute leukemia from MPN;  it is very difficult to treat and very high mortality.
  • The auto-immune conditions and portal vein blockage add complexities to my circumstances. My “youth” is an advantage.


II. I will start a newly-approved medicine called Jakafi to help improve the symptoms of the disease.  
While it won’t slow the progression of the disease, it should reduce the spleen size, night sweats, itching.  May cause more anemia.  I’ll likely need blood transfusions (when hemoglobin falls below 8.0

III. Need to plan for a blood stem cell transplant in the next year or so.
Because of the rapid rate of disease progression, I'm not a candidate for a clinical trial.
We need to prepare for a transplant:

  • “Type” me
  • Look for a match – my siblings, then www.bethematch.org
  • Get insurance & local docs on board with this plan
  • Stay as healthy as possible

I was hoping that a transplant could occur after Alexander graduates high school and heads out to college (mid-2014).  The doctors said that is highly unlikely.  There is a window of opportunity for successful transplants and weekly monitoring of my blood counts will inform us of the timing. That bums me out because I want to be fully present for his last year at home. He said, "Don't worry about me, mom. The sooner you get the transplant, the sooner you feel good enough to do all the things you want to do." 
As long as I make sure he has gas money... (wink, wink)






Wednesday, February 06, 2013

Let's Kick It Up a Notch (or more) -- to Mayo Clinic

I had a Bone Marrow Biopsy done at Northside Hospital on January 24th. The bone marrow biopsy and aspiration report came back with some news:  lots more reticulan fibers and fibrosis "consistent with post-polycythemic myelofibrosis."  The report didn't look good from this patient's perspective but I was pleased that I wouldn't have to wait too long for Dr. Mesa's review.


We decided over the holidays to try to get a consultation with Dr. Ruben Mesa, hematologist/oncologist at Mayo Clinic Scottsdale. I really must thank my mother for making this happen.  She prepared a concise yet thorough letter to Dr. Mesa explaining the changes in my symptoms and asked questions regarding my suitability for a clinical trial that we've been pursuing.  All this before we had the BMB.
  
Dr. Mesa is one of the top experts in the world on Myeloproliferative Neoplasms (MPN), which includes Polycythemia Vera and Myelofibrosis.
Since Mayo Clinic Phoenix is hosting the Joyce Niblack Memorial Conference on Myeloproliferative Neoplasms this coming weekend, we wanted to schedule the consultation for the same trip.  This conference is organized by the MPN Education Foundation and is rich in sharing the latest research in language patients and their loved ones can understand.  This will be the 3rd such conference mom and I will have attended.  I'll be reporting on the conference as it occurs.

So yesterday (Tuesday) I had the initial consult with Dr Mesa. 
Unfortunately, the chronic leukemia has progressed from Polycythemia Vera (PV) to post-PV Myelofibrosis (MF). This means that my bone marrow has gone from producing too many red blood cells to producing not enough of any blood cells (eventually makes one transfusion-dependent).

He explained that all the MPNs are on a spectrum -- my PV appears to be on the aggressive end of the PV spectrum.  [Blood clots in 2007;  uncontrolled hemoglobin and hematocrit in 2009 (when it was diagnosed) to now:  low blood production, unexplained weight loss, increased anemia, bone pain, excessive fatigue, etc.]


Myelofibrosis (both primary and secondary), like the Polycythemia Vera, is a chronic leukemia -- meaning one can live for quite some time with appropriate medications and monitoring.  (Acute leukemias are much more aggressive). 


He needs more info to determine where my MF is in the DIPSS 4 stage range.  It's likely somewhere in the middle -- not early and not severe.  This is good news.

The 20+ pounds I've lost in the last 2 months is likely from increased calories that the cancer is burning.  I'm still not to my Weight Watcher's goal weight, so no concern about it yet.  I finally found an advantage to being chubby ~ it gives cancer more to chew on while the doctors prescribe more toxins to help you get better.

We were hoping that my treatment would change from hydroxyurea to pegylated interferon.  Despite the potential side effects, the peg-interferon has reversed fibrosis in many PV cases.  Unfortunately, the interferon is likely not an option for me now (too late in the disease process AND it may exacerbate the inflammation problems).  We were considering this in 2012 and it never came to fruition. The hydroxyurea (pill chemo) has run its course, too.  No need to continue suppressing the bone marrow.

One of the new JAK-2 inhibitors will likely be a good fit, along with other meds to address the anemia.  He mentioned Jakafi (it's a pill, not an exotic tropical island where cancer patients sun and heal).

There are no medicines to cure secondary MF at this time;  what is available can slow the progression of the disease and reduce the likelihood that it transforms to acute myeloid leukemia.

Before Dr. Mesa develops his recommendations, he needs more information.  So off for more tests:
*  I had lots of blood drawn that is on its way to Mayo Rochester for evaluation.
*  I had a chest X-ray in part because he noticed my fingernails are "clubbing" which is a sign of pulmonary problems.  It could also be a result of all the inflammation.
*  I had an ultrasound on my big spleen and gut.

Dr. Mesa also wants to consult with a rheumatologist for the Behcet's and the other mystery inflammation (see my earlier posts). The inflammation is not related to the blood problems.  While it may not be due to Behcet's, he wants the rheumatologist's opinions. The rheumatologist can't see me until next Tuesday morning, so I have to extend my trip.

Also, he believes that at some point a bone marrow/stem cell transplant may be a good option for me.  This is the only known cure for MF.  He says you don't want to do it too early nor too late in the disease process.  He wants me to consult with their SCT doctor.  That appointment is this Thursday morning.  I'll know a lot more about SCTs as a result.

Dr. Mesa also says that my "youth" is a big advantage (most are diagnosed around age 65). 

The kids know I haven't been feeling well and are glad that I'm seeing a world-renowned expert. Their love and teenage chaos pulls me out of self-centered funks and remind me of all things good. Laughter is truly the best medicine!

I will know a lot more on Friday and will also learn a whole bunch about the state of MPNs and other patients' experiences at the symposium this weekend.

Stay tuned!  Never a dull moment!

Friday, December 14, 2012

MPNs Gain Attention of Hematologists

In case you haven't heard, hundreds and hundreds of hematologists gathered in Atlanta, Georgia for the 2012 ASH (American Society of Hematology) conference this past week.

Until I was diagnosed with Polycythemia Vera, I had no inkling how complicated our blood is.  I also didn't realize how much 'we' (including the medical and scientific communities) don't know about about blood functions at the protein and molecular levels. 

It's a beautiful thing when blood functions properly.  But when it doesn't, well, it turns a person into a patient. 

Fortunately, we've got some very inquisitive, intelligent people studying many aspects of MPNs.  This year's conference featured several presentations on new learnings about Myeloproliferative Neoplasms (MPNs) -- from PV phenotypes to drugs that impact the disease processes and side effects like anemia.  

Here are a few helpful summaries of the MPN highlights from the conference.  The videos features Dr. Ruben Mesa of the Mayo Clinic, Scottsdale, Arizona.

Dr. Ruben Mesa summarizes MPN updates from ASH conference  
(updates on Polycythemia Vera and Ruxolitinib in Myelofibrosis patients)

In the next video, Dr. Mesa discusses the molecular abnormalities of MPNs (especially those with Polycythemia Vera):

Genetic Profiling Shows Promise for Customized Treatments

I want to learn more about this, as each fellow PV-er I meet seems to have a unique experience.  Varied severity of symptoms, responses to treatments, and outside factors make living with MPNs all the more frustrating.  Human beings want certainty, predictability, and a sense of control.  

It seems we are in the midst of the MPN learning curve.  At this point in human history, we can be grateful for the forward momentum of knowledge in this relatively obscure area of blood science.

Check out the ASH website.

Tuesday, November 15, 2011

The Traffic Jam Within: A Primer on Blood Clots and Thrombosis


The 6th Annual International MPN Patient Symposium began with Dr. Babette Weksler giving us a fascinating overview on the invisible threat to people living with Polycythemia Vera (PV) and Essential Thrombocythemia (ET):  thrombosis.

Dr. Weksler is with the Weill Cornell Medical College and Center.  She has studied and treated patients with thrombosis for over 35 years.  Dr. Weksler focuses on diseases of platelets, bleeding and thrombotic disorders, sickle cell anemia, and immunologically mediated blood disorders.  She is a teacher, researcher, and clinician.

This article includes some blood basics along with the specialized information provided by Dr. Weksler.

We all have arteries, which flow blood from the heart to the rest of the body and veins, which return blood from various organs and parts of the body back to the heart.

There are “major” (large) and “minor” (smaller) veins and arteries throughout the body system.  There are also capillaries (very small passageways) for blood to move through the system.

Remember, the blood clotting function is necessary for us to heal wounds and prevent excessive bleeding.  Thrombosis is when the blood clotting function works against the body’s interest (also called “dis-regulated clotting”).   A thrombosis can fill a vein or artery and prevent blood from flowing to its intended destination.  This causes blood to back up, organs to suffer, and often end life as we know it.  This happened to me;  the cascade of problems from three blocked veins is now legendary in my family.

Sometimes a clot gets pushed from where it formed to an organ; this is called an “embolism.”  An “embolism” is an obstruction of a blood vessel (typically a blood clot) that travels through the bloodstream and lodges, resulting in loss of blood flow.  The embolus could be a blood clot, fat mass, air bubble, or other mass.  The most common is a blood clot in the leg gets pushed up into a lung and causes trauma or
death.

So... clots are good;  thromboses are bad.

An “aneurism” is when the wall of a blood vessel (vein or artery) bulges out and weakens.

Anatomy of a Blood Clot:
The clotting function produces fibrin strands, creating a mesh;  then platelets contribute to clot initiation and firmness of the mesh.  Red blood cells get trapped in the mesh and give the clot bulk.

Dr. Weksler explained that the clots in MPN patients are different from blood-healthy patients.  People with MPNs experience thrombosis due to their blood composition and abnormal functioning of the blood, endothelium, and platelets.

Hemostasis is limited clotting that preserves the integrity of blood vessels and maintains normal blood circulation.  It is important to maintain the vascular integrity (healthy blood vessels) and normal blood flow despite continual minor injuries.

High hemoglobin (Hb) in Polycythemia Vera leads to high blood viscosity (thickness), which slows blood flow and leads to thrombosis.  Think about a milkshake going through a straw compared to water).  If the milkshake contains small bits of fruit, it can get clogged in the straw.

The abnormal vessel wall favors thrombosis and blocks clot dissolution.  If the vascular integrity is compromised (blood vessels are weak or damaged) the risk for clots and thrombosis is increased.

Blood clots and thrombosis are frequent in Polycythemia Vera (PV) and Essential Thrombocythemia (ET).
They occur in both veins and arteries, and in large and small vessels.  Clots and thrombosis are major contributors to morbidity (death) for MPN patients.

Interesting note:   Both clots and excessive bleeding may occur in the same person at the same time or different times.

The Why:  Pathophysiology of Thrombosis in MPNs
It is generally understood that when blood stops moving, it clots.  For example, in Polycythemia Vera, a high red blood cell count (seen in high hematocrit) can block small vessels and slow blood flow.  Did you know there are other causes?  I didn’t.

Dr. Weksler offered the clearest explanation I’ve heard of the many ways MPNers experience clots.
There are four different causes of Blood Clots:

1. Endothelial Activation
The endothelial cells line the veins and arteries.  They issue commands to the blood elements and certain organs.  With MPNers, the endothelial cells may shift from non-reactive/anti-thrombotic to pro-thrombotic surface properties.

2. Platelet Activation
Sometimes platelets are activated for enhanced adhesion, aggregation, secretion.  The platelets then gather together and form a clot mesh that catches RBCs that try to flow through the vessel.

3. Blood Coagulation
The blood can initiate the clot when its viscosity (thickness) is increased and thereby slows the flow.  The thick blood can also cause increased thrombin generation and fibrin formation, causing clot formation.
Blood coagulation can also cause decreased fibrinolysis (the body's natural way to break down clots).

4. Red Blood Cells
The RBCs also sometimes push platelets to sides of blood vessels where platelets can interact with vascular endothelial cells.  The RBCs trigger the response by the platelets and endothelial cells.   This can cause microscopic clotting of the platelets.

Dr. Weksler also discussed several differences between Arterial and Venous thrombosis:

Arterial (arteries – taking clean blood from the heart to the body) thrombosis:
Arteries are the fast flow system.
Endothelial injury key
Platelets initiate when activated
“White clots”
Primary preventive treatment:  Antiplatelet therapy (e.g., aspirin)

When the platelet count is over 1 million or 1.5 million, it promotes bleeding:
Acquired von Willebrand (vWD)
These platelets absorb von Willebrand factor, an important clotting factor, resulting in mucosal bleeds.

Venous (veins – taking “used” blood from the body to the heart) thrombosis:
Veins are a slow flow system
Venous stasis key
Fibrin formation mainly;  platelets less involved
“Red clots”
Primary preventive treatment:  Anticoagulant therapy mainstay  (e.g., warfarin)

What are the chances I’ll experience thrombosis?
If you meet any of the following criteria, you are at higher risk for a thrombosis than the general population:
• Advanced age (>65 years of age)
• Control of MPN anti thrombosis with medication
• Prior Thrombosis
• JAK2 mutation burden *
• Acquired risk factors:  hypertension, high cholesterol, smoking, diabetes, CV disease
• Inherited thrombophilia

Persons with Polycythemia Vera have a 33% risk of a major thrombotic event.
Persons with Essential Thrombocythemia have a 17% risk of a major thrombotic event.

*  The JAK2 mutation burden affects thrombosis in MPN patients due to:
1. More immature and activated platelets
2. Higher numbers of activated WBC
3. More RBC precursors capable of epo-independent growth

Interesting Note: In Essential Thrombocythemia (ET), the presence of JAK2 mutation increases the risk of arterial thrombosis.

Platelet-Leukocyte aggregates and micro-particles promote thrombosis.  The different kinds of cells can act together to promote thrombosis.

To reduce the risk of a thrombotic event, MPN patients should lower the hematocrit (HCT) to normal (men <45%, women 42%).  This decreases blood viscosity.
Note:  If one only lowers platelet count, thrombosis may still be a risk.  

Role of Various Drugs with Thrombosis (clots):
• Hydrea inhibits Tissue Factor expression, decreases platelet-leukocyte aggregates, and decreases the immature platelets
• Aspirin relieves erythromelalgia (excessive dilation of blood vessels of feet or hands)
• Interferon preferentially decreases JAK2+clones
To date, JAK2 inhibitors have not decreased thrombosis

For those of us taking warfarin (Coumadin), Dr. Weksler said that the newer anti-coagulants are “not there yet”.  Some patients have tried Pradaxa and gone back to warfarin.  Pradaxa must be taken twice a day consistently and this is problematic for many patients.  She believes that we’ll have a better alternative in a few years.

Here are my take-aways:
  1. There are several different ways our blood may clot and then thrombose (sounds grandiose, doesn't it?!).
  2. Aspirin reduces one kind of risk (arterial clots). 
  3. Warfarin/Coumadin reduces another kind of risk (venous clots).
  4. Hydrea reduces yet another kind of risk (platelet-leukocyte aggregates).
  5. All the preventive treatments must be closely monitored by your physician.  If the blood levels get out of whack (CBC and for those on warfarin, the INR), thrombosis can occur.  
  6. It is possible to suffer from a thrombosis AND internal bleeding at the same time.
  7. PVers and ETers have different blood thrombosis challenges.
  8. Women's hematocrit should be at or below 42%.
  9. Men's hematocrit should be at or below 45%.
  10. Endothelial cells can influence the blood that flows through the blood vessels.  This is a leading edge in study.
I am grateful for those with healthy blood who donate regularly.  Our MPN blood, when taken out by phlebotomy/venesection, can not be shared with others;  thanks to Dr. Weksler, I understand why.

Wednesday, November 02, 2011

A Few Quick Thoughts from the MPN Patient Symposium


I just got back home from the whirlwind trip to New York City for the 6th International Patient MPN Symposium sponsored by the MPN Research Foundation and the Cancer Research & Treatment Fund.  The day was filled with fascinating speakers (several of whom were new to me) and each of them taught me something new.

I'll organize the 25 pages of notes later, but I thought I'd tempt you with these nuggets. :)

Cool Terms I Picked up at the MPN Patient Symposium

Somatic mutation:  a change in a gene that occurs after birth (you aren’t born that way)

Molecular mimicry:  some genes mimic others

Epigenome:  the new area for research

We are all entitled to our own opinions, but not our own facts.

JAK2 and Exon 12 and TET2 – a few of many mutations under exploration

Genomic Instability:  affects the micro environment and what happens with MPNs

Specialized Niche Cell:  cells that are highly specialized (example:  Endothelial cells)

Endothelial cells:   lining of blood vessels;  they also instruct other cells and broadcast directions throughout the body.  They also instruct organ regeneration (eg, liver and lungs). 

Inductive angiogenesis:   uh, i forgot already!

Proliferative angiogenesis:   forgot this one, too!

Role of vascular niche cells in self-renewal of stem and tumor cells:
The micro environment that are created by the mutations have huge impact on what happens. 

Angiocrine Factors                

Niche cell:  activate endothelial cells

Leukemic initiating cells – they expand the vasculature in the bone marrow.


Factoids and A-Ha’s! 
  • Platelet-Leukocyte aggregates and micro-particles promote thrombosis.  The different kinds of cells can act together to promote thrombosis. 
  • We need drugs that target the endothelial cells.   Endothelial cells expand hematopoietic stem and progenitor cells by angiocrine expression of Notch ligands.
  • The first hematopoiesis occurs with the endothelium. 
  • The leukemia from MPNs is completely different from the normal leukemias.  We need different treatments because the biology is different.
  • The Chronic Myeloid Leukemia is triggered by the Philadelphia chromosome, so it is regarded as a different disease process from MPNs.
  • JAK2 is not a “switch” that can be flipped on or off; it has at least 10 different mutations, which cause different disease results in patients.

JAK2:  The One Mutation, Three Diseases problem.
Why do patients develop ET, PV, or PMF?
Level of JAK2 allele burden determine ET, PV or PMF – more so in men than women
How much is the disease versus the host predisposition to develop an MPN?
Are there other cooperating somatic mutations?
  • Despite all the advances, we still have a long way to go – do not be misled by where we are.

  • For those of us taking warfarin (Coumadin), Dr. Weksler said that the newer anti-coagulants are “not there yet”.  Some patients have tried Pradaxa and gone back to warfarin.  Pradaxa must be taken twice a day consistently and this is problematic for many patients.  She believes that we’ll have a better alternative in a few years.
  • Much of the knowledge gained and progress made has occurred because patients before us and among us have shared their tissue samples, DNA, and whole selves for testing and clinical trials.

There was so much more covered.  I hope this tempts you to watch the video when it is available online at the MPN Research Foundation

Stay tuned!
peace,
Marina

Sunday, February 27, 2011

Myeloproliferative Neoplasms Conference - Day 1 Highlights

More than 200 cancer patients, supporters, and physicians/researchers gathered at Mayo Clinic Scottsdale this morning at 8 am to begin a lively conference about the state of knowledge and treatment of the Myeloproliferative Neoplasms -- Essential Thrombocythemia, Polycythemia Vera, and Myelo Fibrosis.


Dr. Ruben Mesa opened the session and welcomed everyone and reminds us that this conference is because of Joyce Niblack.  Her husband Bob carries on her work through the CMPD Education Foundation with this Biennial Conference.

It will take some time to prepare proper notes from the conference, as the presenters had visual presentations and talked quickly.  When I get all the information together, I will post a complete written report.



Here are a few nuggets from today:

The hematocrit that feels best for you is where you should be.   While some people feel good at 42 or 45, others may need it lower to feel good, like 38 - 40.  Don't let your doctor get stuck on a prescribed number if it doesn't feel good for you.

Don't worry about tracking your JAK2 allele burden over time;  we don't know that it has any clinical relevance.  All the drugs today inhibit the JAK2.

JAK2 inhibitors are unlikely to eliminate the disease.

Whole exome sequencing to identifyMPN alleles and gene sequencing is becoming more affordable.
Soon there will be a lot of data; they will be able to learn to identify what genes cause the transformation to leukemia.

In your genes:
2 copies of JAK2 => PV
1 copy of JAK2 => ET


Future in drug therapies:  combine drugs in rational combinations to facilitate next level of clinical trials

Prolonged use of interferon can reverse fibrosis in the bone marrow (does not cure the disease).

Help for Pruritis (itchy skin):

  • JAK2 inhibitors are good.
  • Interferon is better than HU.
  • UV narrow band B works 70% of time (see dermatologist)
  • Weight wraps (prednisone in a wrap) (see dermatologist)
  • Aprepitant, an anti-emetic, works on the Substance P

Formication:  the sensation of ants crawling on your body.

Hematopoietic Cell Transplantation (HCT):
The only treatment that has potential for a cure for MPNs is the stem cell transplant.

Pegasys (Pegylated Interferon) is more potent than regular Interferon-a.  The dose is not so important as the duration.  The effect is probably due to your own biologic abilities.

Standard practice regarding Phlebotomies:  no more than 4 per year.

If you are going to get a splenectomy, go to one of the half dozen surgeons who have done the procedure on MPN patients.  Removing the spleen has real risks:  clots in the area;  5-6% mortality (similar to open heart surgery).

When to have another Bone Marrow Biopsy (BMB)?  only if concerned the diseased has progressed to Myelofibrosis.


That's all for now!

Friday, February 25, 2011

Calling All Folks Living with ET, PV, & MF

MPN Upate:
The 6th Biennial Joyce Niblack Memorial Conference on Myeloproliferative Neoplasms kicked off today with a great luncheon at Alchemy restaurant in Fountain Hills, Arizona.  Bob Niblack ordered perfect weather so we could enjoy an outdoor buffet and meet others in the journey with MPNs.  

There are many smiling faces;  this has to be the friendliest group of blood cancer patients!
It is so refreshing to meet others who "don't look sick" on the outside yet have so much going on in the bloodstream.  

I am attending the conference with my mom, Eileen, and together we'll be recording notes of the presentations for the next two days.  I'll then post them and share with others who cannot be here.  They will also be helpful for later reference.  Photos will come when I get them uploaded.

Stay tuned for the latest in MPN news brought to you by the CMPD Education Foundation & Mayo Clinic, Scottsdale.
Cheers!

Friday, December 10, 2010

MPD Foundation's latest Symposium & Other Good News


Those of us living with rare bone marrow-based blood cancers (myeloproliferative neoplasms) can find helpful information and support through the MPD Foundation (www.mpdfoundation.org).

Based in Chicago, the MPD Foundation sponsors patient-physician symposia across the United States, stimulates research for new treatments (and eventually cures), and fosters collaboration in many ways. I'm a big fan of the organization -- not only its mission, but the people who make it happen. By website and by phone, the MPD Foundation was helpful and reassuring when I was first diagnosed with polycythemia vera.

On October 25th, the MPD Foundation hosted a patient educational symposium at the University of California San Diego Moores Cancer Center in La Jolla, California. They brought in experts from leading institutions to share the latest in the range of research, clinical trials, the patient experience.

One of the experts is a patient who went through a bone marrow transplant and now lives with chronic Graft vs. Host Disease. You can read more and view the symposium video on the MPD website.

This month, the MPD Foundation represented us patients at the American Society of Hematology meeting. Because the MPDs (I guess we need to get accustomed to calling them MPNs) are rare compared to all the other blood cancers, their presence reminds practitioners that PV, ET, and MF patients are in their communities. They also make practitioners aware of local MPD support groups across the country.


In other news...

I've seen a few queries on various MPD listservs and posts (and I asked this myself when I was diagnosed with Polycythemia Vera one year ago):

Is PV/ET/MF considered cancer?
The question may not seem important, but it is for several reasons:
1. health insurance and disability insurance coverages are impacted based on illness codes.
2. naming "it" helps you come to terms with what's going on in your body.
3. it simplifies the explanation to the casual inquirer.

And now it's official! You've got a Cancer.
The World Health Organization (WHO -- not to be confused with "The Who") officially reclassified the myeloproliferative "disorders" as "neoplasms" (meaning "malignancies" or the dreaded "cancer").

This reclassification will help patients who need the chemotherapies to survive get the coverage they need from their health insurance. Believe it or not, all insurers are not up to speed on indicators for polycythemia vera, essential thrombocythemia, and primary myelofibrosis; current standard treatments; and promising off-label treatments.

Fighting a disease and fighting a bureaucracy at the same time is doubly exhausting!

The good news is that we can be living testimony that "Cancer" does not set an immediate expiration date. While there is yet no cure, we can live with these pesky diseases for quite some time as long as we take special care of and listen to our bodies.


There is still some conflicting information on the web:

www.cancer.org (American Cancer Society) still refers to MPNs as "chronic disorders and diseases"

www.lls.org (Leukemia & Lymphoma Society) refers to them as "clonal diseases" but the fact sheets are in the leukemia category.

Funny / True Story:  

Someone actually called me a few days after we had a conversation about my friend "Polly" and said, "Hey! I've got great news for you! I looked up polycythemia on the ACS website and it's a disorder, not a cancer!"

It was then I was reminded that words hold emotions for us all. While the word didn't change a single thing about my condition, this person felt a lot better. What should I say? I'm so happy for you? We hadn't spent a lot of time on the "C" word, so I was a bit surprised. I explained that I wasn't angling for the cancer label. The shift from "disorder" to "neoplasm" was fairly recent and because the MPDs don't afflict a large number of people, the news might not have reached the ACS webmaster yet.
Sometimes it just is what it is...


Monday, April 12, 2010

The Beauty of a Competent, Caring Physician

My kids have heard me say many times, "Never underestimate the power of your smile.  It may be the one nice thing someone receives today."

To physicians, I say "Never underestimate the power of your intentional listening.  It may be the relief your patient needs when there is no cure for what ails them."

I recently had two such pleasant experiences in one week with doctors I had not met before.  After 20 days of a Behcet's ulcer that was proving to be more resilient than its host (me), I got an emergency appointment with Dr. Giardina, a gynecologist with Kaiser Permanente who was kind and sympathetic.  He admitted he hadn't seen a Behcet's case before, but he was familiar with the disease (that it is an auto-immune disease and very rare).   He provided some pain relieving creme and antibiotic ointment to tide me over until my appointment with a rheumatologist two days later.  It's the same "good stuff" they use on baby boys when they are circumcised.

That Thursday, I met with Dr. Andres Salazar, a rheumatologist with Kaiser Permanente.  Fortunately, he is familiar with Behcet's Disease and reviewed my case before he entered the exam room. 
[side note:  This was an important visit for me because not only was it my first appointment with him, but my family was leaving for a Spring Break holiday the next day.  My husband and I weren't sure if I would be able to make the long trip comfortably since the Behcet's wasn't healing.  I was prepared to venture on, but dear hubby wanted the doc's opinion.]

I took prednisone daily for the first year to manage the flare-ups, but the side effects proved hazardous to my physical, emotional, mental, and marital health.  Since I stopped taking the prednisone in January, the flares have been more frequent and take longer to heal.  This, he says, further confirms the Behcet's diagnosis.  In addition, I now have arthritis in my hands, hips, and ankles.  All I need is the dowager hump and I'll be walking like Quasimodo!

Dr. Salazar also explained that the meds that are most effective for Behcet's also affect the bone marrow.  Since the Polycythemia Vera is a bone marrow malignancy, we need to tread lightly on this.  He is going to confer with Dr. Kondapaneni, my hem/onc about the next course of treatment.  

I am just one year into the disease, so there is still a good deal to learn about which of my systems are affected by Behcet's.  He ordered a lot more blood work and we'll reconvene in a few weeks.   I've also got to go to an ophthalmalogist to be checked out for uveitis;  while I doubt there is any involvement in the eyes,  I do have some vision issues, so we need to check it out.

Did either of these doctors solve my problem?  No.  But they listened to my concerns (I felt heard), recognized the illness (I'm not crazy, making this up), acknowledged and treated the pain (they understood this hurts like hell), and continued probing for more information by asking me questions and doing more lab work (willing to gather more information to determine next course of treatment).

I left my appointment with Dr. Salazar feeling better than I had felt in weeks simply because he displayed competence and thoughtfulness during my appointment.  

Living with chronic illnesses can be a part-time or full-time job (depending on the type and severity).  We get to live with the symptoms, manage multiple medications & their side effects, endure the funky things the illnesses throw our way, go to doctor's appointments, lab visits, deal with insurance companies, etc.
When we are fortunate to find physicians who treat the patient and his/her illness with attentiveness and compassion, it's amazing how much better we feel.

In my daily practice of gratitude, I am thankful for medical professionals who remember that their patients are people -- with names, lives, families, histories, hopes, and desires.  It's challenging, I'm sure.  Doctors don't see us patients when we are at our best.  And they have a host of pressures outside their 15-20 minute appointment with each patient.

When you work with physicians or other medical professionals who are competent and kind, let them know you appreciate them.  Don't we all like to feel the love?

Thursday, January 07, 2010

Hematology Experts Raise Hope and Spirits!

I remember a day when Katrina was a little girl working intently on one of her self-initiated projects. I asked her a question and she said, "Mommy, I just don't know. My mind is full right now!" She put her fingers on her temples for emphasis. Not only was that foreshadowing of the intense personality that was developing, she taught me a phrase I find myself using a lot lately.

My mind is full! And I feel affirmed and understood -- two great gifts today.

This morning, Robert and I went to our much anticipated appointment with Dr. Elliott Winton, a hematologist at Emory's Winship Cancer Institute in Decatur, Georgia. (http://cancer.emory.edu/)

After researching as much as I could on-line, connecting with other patients living with Polycythemia Vera and other Myelo Proliferative Neoplasms, I couldn't wait to sit with someone who literally studies and thinks about these rare blood cancers on a daily basis. Yes, I finally said the "c" word; the science world has raised this blood disease group from a "disorder" to "neoplasm" which means malignancy. That's okay -- I can live with it. I call it "Polly." The personification helps me focus my frustration on this "thing" that has a lot of control over my life.

Dr. Winton studied my medical history of the last two years (sent over by Kaiser Permanente) as well as information Emory kept on file from tests I had there in 2003 (which I had long forgotten). He noted that there was evidence of an MPN in 2003 when my bloodwork showed high platelets and low hemoglobin. At that time, he said, they wouldn't have made the diagnosis, as the breakthrough scientific discovery of the JAK-2 protein gene mutation didn't occur until 2005.

In October, 2007 I experienced thrombosis (clots) of the portal, splenic, and superior mesentary veins. Those clots caused a cascade of additional health issues which I've described in posts on this site from around that time. Dr. Winton explained that these types of clots in the gut are major indicators of an MPN, but because they occur so rarely, the JAK-2 test sometimes isn't ordered and the diagnosis is missed. I have been on an anti-coagulation regimen of warfarin (coumadin) ever since. This treatment has staved off more clots; it does nothing to address the root source of the problem.

I also began taking iron pills again after the surgery to address the anemia that resulted from blood loss from surgery. Guess what? That triggered more red blood cell production -- a natural process, just aggressive for someone with PV.

I never regained my full steam after the surgery and within a year, had to quit my job at The IMPACT! Group. I simply didn't have the stamina to meet the needs of the organization. Little did I know that my bone marrow was working over time. I was tired all the time and couldn't push through it.

By the spring and summer of 2009, I noticed my toes and fingers turned purple intermittently. The doctors shrugged this off and were unconcerned. By July I was itchy and in August, my left ankle began to swell, turned red/purple, and became painful. I went to the doctor in September; a wonderful internist ran some blood work and called me the next day to let me know that there are some concerns (my hematocrit was almost 70) and I needed to see the hematologist immediately. My blood pressure also went through the roof.

We started with twice weekly phlebotomies and then added Hydroxyurea (HU) chemo pills to bring the hematocrit level to a healthy range.

Dr. Winton shared that a hematocrit that high is rare, even for someone with an MPN; that it is amazing that I didn't have a stroke or worse. I knew it was serious and I knew I was scared; I didn't know that it was my second "close call" in two years!


Dr. Winton provided a clear and interesting lesson in the types of blood cells (can you name them? T-cells, B-cells, Red Blood Cells, Granulocytes, Monocytes, and Platelets) and how they are made in the bone marrow, differentiate, and eventually die (apoptosis).

He explained that the JAK-2 mutation that has occurred in me presently affects the proliferation of the stem cells that create red blood cells (that's the polycythemia vera type of MPN).

Note to reader: If you read this and there are inaccuracies or errors, they are due to my limited memory and poor note-taking. They are not to be attributed to Dr. Winton. I did not run this by him before hitting "publish post." Mea culpa in advance.
The clinical problems created by Polycythemia Vera can include:

1. Clotting & bleeding which can trigger strokes, heart attacks, etc.
This is treated with anticoagulation medications (I'm on warfarin/coumadin blood thinner because I had the major thrombotic event in October 2007). There are supposed to be some better drugs coming on the market in the next couple of years (yeay!) Other patients who have not had blood clots take "baby" aspirin -- 81 mg/day. This occurs in about 1/3 of the patients.

2. Myelofibrosis -- the PV also increases production of collagen in the bone marrow and extra medulary hematapoeisis (when blood is created in the spleen and/or liver).
This would be treated by decreasing the JAK2 clone size.

3. Acute Leukemia -- well, this is just not a good thing; very limited time on the planet. This happens in 3-5% of the patients.

So... How do we decrease the clone size?
Thankfully, there are scientists all across the globe working on this.

Right now, the only known cure is a Stem Cell Transplant.
Emory does "mini transplants" where some of the patient's stem cells remain, but receives many more from the donor.
That requires typing my cells and those of potential donors (siblings are most likely matches). It would require a 1 month hospital stay.
The downside? For a person of my age, there is a 15% mortality rate.
So this is not a wise option at this stage of the disease. I will pursue more information on this option as a Plan C or D, as it is better to prepare early rather than wait for an acute situation and have everyone scrambling.

The second option is Interferon. This chemo treatment slows the myelofibrosis, but the most common side effect is feeling like you have the flu all the time. No thanks!
There is a pegylated version (I think they use Roferon instead of Interferon) that requires just one injection a week and the side effects are minimal for most patients with the dosage appropriate for them. There is a Phase II trial coming up for this in about 6 months.
Most insurance does not pay for this yet, so some patients try to get into trials.

The third option is Hydroxyurea (HU) or Hydrea. This 40 year old chemotherapy slows the proliferation of the red blood cells. I am currently taking 500 mg of HU daily. The dosage level at 1,000 proved to be too much for me (resulted in the most awful sores in inconvenient places). There are other side effects of the HU that are annoying but bearable.

The fourth and most exciting option is on the horizon: JAK-2 Inhibitors.
There are several drugs in the pipeline that are a few years away from being ready for prime time.


So what is next for me?

1. Pay close attention to my hemaglobin level (must stay below 42).
2. Pay close attention to my INR (coagulation ratio) -- must stay between 2.0 and 3.0
3. Get a Bone Marrow Biopsy -- to gauge the progression of the disease process and Type my bone marrow for possible stem cell transplant in the future.
4. Additional tests (like D-Dimer) to gather enough information on my situation for the experts to determine what clinical trials might be appropriate for me.
5. See if my blood pressure can be stable in these conditions without the nadolol.

If you've read this far, I hope you can see how good it feels to be affirmed and have a plan of action. I'm in it to win it! It is humbling to be in this situation at a time when scientific discoveries are happening in this rare blood disease area.

My experience with Polycythemia Vera will be added to the international data base of patients and contribute to future study and hopefully discoveries. (I'm not worried about privacy. By this point, I'm essentially uninsurable in the US with these significant pre-existing conditions. If Robert lost his employment with a large company, we'd be in a sticky wicket. But I'm not borrowing any more trouble right now, thank you!)

You know I don't like roller coaster rides. But after my session with Dr. Winton, I feel like I can handle a few more bumpy rides -- with a reasonable plan and little help from my friends.

Polly kept me from traveling with Robert and the kids to Beaver Creek, CO for a couple of days skiing this week. My family is the greatest and I'm so glad that we didn't let Polly "win" by completely spoiling the family trip. Polly also brought some good friends to me to pass the time in my family's absence. Gratitude is a gift one gives to oneself. I am grateful!